What is the appropriate treatment plan for a patient with adhesive capsulitis of the shoulder and uncontrolled type 2 diabetes mellitus with an HbA1c of 11.6%?

Dual-Priority Treatment: Aggressive Diabetes Control Plus Conservative Shoulder Management

For a patient with adhesive capsulitis and severely uncontrolled diabetes (A1c 11.6%), you must immediately intensify diabetes management with metformin plus a GLP-1 receptor agonist (preferred) or SGLT-2 inhibitor while simultaneously treating the shoulder conservatively with physical therapy and corticosteroid injections, recognizing that poor glycemic control will significantly compromise shoulder treatment outcomes.

Critical Context: Why Diabetes Control Takes Priority

Your patient's A1c of 11.6% represents severe hyperglycemia that fundamentally undermines adhesive capsulitis treatment. Diabetes is an independent predictor of treatment failure in adhesive capsulitis, with diabetic patients showing 3.69 times higher odds of developing the condition and significantly worse treatment responses across all interventions 1, 2. Patients with diabetes experience:

• Higher relapse rates (20% vs 4.7%, p=0.008) 3
• More frequent need for reintervention 1, 3
• Persistently higher pain scores post-treatment (p=0.022) 3
• Reduced range of motion improvements, particularly at 6 months (p<0.01 for forward flexion, p=0.02 for external rotation) 4
• HbA1c ≥48 mmol/mol (6.5%) is specifically identified as a predictor of treatment failure 1

At 11.6%, your patient is far above this threshold, making diabetes optimization non-negotiable before expecting meaningful shoulder improvement.

Step 1: Immediate Diabetes Management Intensification

First-Line Pharmacologic Approach

Add a GLP-1 receptor agonist to metformin (if not already on metformin, start both) 5, 6. This is the preferred choice because:

• GLP-1 agonists reduce all-cause mortality, major adverse cardiovascular events (MACE), and stroke 6
• They provide superior A1c reduction from severely elevated baselines
• Weight loss benefits may help address obesity (a co-risk factor for adhesive capsulitis)
• They avoid hypoglycemia risk that would complicate physical therapy

Alternative: SGLT-2 inhibitor if GLP-1 RA is contraindicated or not tolerated 6. SGLT-2 inhibitors reduce all-cause mortality, MACE, chronic kidney disease progression, and heart failure hospitalizations 6.

Insulin Consideration

Given the A1c of 11.6%, consider adding basal insulin if symptoms of hyperglycemia are present or if the patient cannot tolerate/access GLP-1 RA 5:

• Start with 10 units daily or 0.1-0.2 units/kg
• Titrate by 2 units every 3 days targeting fasting plasma glucose goals
• Use evidence-based titration algorithms 5
• Critical caveat: If you add insulin, prescribe glucagon for emergency hypoglycemia 5

Reassessment Timeline

Reassess glycemic control every 3 months and modify therapy to avoid therapeutic inertia 5. Target A1c between 7-8% for most adults 6, though individualize based on hypoglycemia risk and comorbidities.

Step 2: Conservative Shoulder Management (Concurrent with Diabetes Control)

Initial Conservative Treatment (First 9-12 Months)

Begin with physical therapy combined with intra-articular corticosteroid injection 7, 8:

• Early corticosteroid injections are associated with shortened symptom duration and improved functional scores 7
• Lower doses (10 mg vs 40 mg) may provide better pain relief and functional improvement 7
• Rotator interval approach may be superior to posterior approach 7

Alternative Conservative Options

If corticosteroid injections are contraindicated due to diabetes concerns:

• Extracorporeal shock wave therapy avoids potential metabolic complications from steroids in diabetic patients 7
• Ultrasound-guided hydrodilatation with hyaluronic acid combined with physical therapy shows superior outcomes compared to PT alone 7

Important caveat: Hydrodilatation in diabetics shows effectiveness but with significantly diminished results compared to non-diabetics 3, 4. This reinforces why glycemic control must be optimized first.

Monitoring Shoulder Progress

Assess at 3-month intervals:

• Visual analog scale (VAS) for pain
• Passive range of motion (forward flexion and external rotation)
• Functional scores (DASH score)

Expect slower improvement in diabetic patients, particularly if glycemic control remains suboptimal 9.

Step 3: Surgical Intervention (If Conservative Treatment Fails After 9-12 Months)

Consider arthroscopic capsular release, manipulation under anesthesia (MUA), or both only after 9-12 months of failed conservative management 7, 8:

Surgical Options

• Arthroscopic capsular release: Allows direct visualization, reduces MUA complications (fracture, dislocation, nerve injury) 7
• MUA: More cost-effective but higher complication risk 7
• Combined approach: May be appropriate based on intraoperative findings 10

Critical finding: In diabetic patients, no single surgical treatment modality is superior to another for final range of motion 10. This means surgical choice can be based on surgeon preference and patient factors rather than diabetes status alone.

Post-Operative Protocol

Emphasize early physical therapy with multimodal pain management to maintain and improve ROM 7. This is crucial in diabetic patients who may experience loss of external rotation post-operatively (more common in MUA+capsular release group, p=0.03) 10.

Common Pitfalls to Avoid

1. Treating the shoulder without addressing diabetes: This guarantees suboptimal outcomes and high recurrence rates
2. Delaying diabetes intensification: With A1c at 11.6%, waiting for "lifestyle modifications alone" wastes critical time
3. Using sulfonylureas or long-acting insulin as first add-on therapy: These are inferior to GLP-1 RA and SGLT-2 inhibitors for mortality and morbidity reduction 6
4. Premature surgical intervention: Most adhesive capsulitis is self-limiting; surgery before 9-12 months of conservative treatment is rarely indicated 7, 8
5. Ignoring female sex as additional risk factor: If your patient is female, expect even higher reintervention rates (p=0.036) 1

Integrated Care Approach

Coordinate with endocrinology or primary care for diabetes management while you manage the shoulder 6. Health systems should assess social risk factors and connect patients to community services that support diabetes self-management 6.

Include diabetes self-management education and support (DSMES) as part of the treatment plan 5. This reinforces behavioral interventions (weight management, physical activity) that benefit both conditions.